** Shares of drug developer Vistagen Therapeutics VTGN.O falls 3% to $0.60 premarket

** Co says it cut 20% of its workforce on March 5 to manage cash and support its Palisade program clinical studies

** Expects cash runway to now extend into 2027

** Palisade program includes studies of its experimental nasal spray for mental health conditions, aiming to offer faster-acting treatment options - VTGN

** Co says the job cuts will have immaterial costs and affected employees may receive cash severance and temporary healthcare coverage

** VTGN fell ~66% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))